Evidence map›Paper›PMID 42782852›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice.

Tina Yu Xuan Luo, Sila Usta, Eric McGinnis, Cheryl A Mather, Julie Bergeron, Tanya Gillan, Etienne Mahe, José-Mario Capo-Chichi, Philip Berardi, Paul C Park and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tina Yu Xuan LuoBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Sila UstaBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Eric McGinnisVancouver General Hospital, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Cheryl A MatherMolecular Pathology (North Sector), Alberta Precision Laboratories, Edmonton, AB T6G 2B7, Canada.ORCID 0000-0001-5164-5309
Julie BergeronCEMTL Installation Maisonneuve-Rosemont, University of Montreal, Montreal, QC H1T 2M4, Canada.ORCID 0009-0008-2911-8631
Tanya GillanDepartment of Pathology Central Zone, Nova Scotia Health, Halifax, NS B3H 1V8, Canada.ORCID 0009-0008-2278-9950
Etienne MaheDepartments of Pathology & Laboratory Medicine, and Division of Hematology & Hematological Malignancies, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.ORCID 0000-0002-6559-9339
José-Mario Capo-ChichiDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
Philip BerardiDepartment of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0002-2302-6145
Paul C ParkDepartment of Pathology, University of Manitoba, Winnipeg, MB R3E 3P5, Canada.
Doha ItaniDepartment of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Ashish RajputPathology and Laboratory Medicine, Newfoundland Health Services, St John's, NL A1B 3V6, Canada.
Benjamin Chin-YeeSchulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0003-0737-3603
Fei-Yu HanLaboratory Medicine, Memorial University, St. John's, NL A1B 3V6, Canada.
Darci T ButcherDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
Jennifer FesserTransfusion Medicine and Laboratory Hematology, Queen Elizabeth Hospital, Health PEI, Charlottetown, PE C1A 8T5, Canada.
John DeCoteauDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Graeme QuestDepartment of Pathology and Molecular Medicine, Queen's University, Kingston Health Sciences Centre, Kingston, ON K7L 3N6, Canada.
Elizabeth McCreadyDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.ORCID 0000-0002-7952-2279
Hubert TsuiBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.ORCID 0000-0001-7943-9099

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical decision making in Acute Myeloid Leukemia (AML) critically relies on rapid genomic characterization. To better understand the AML diagnostic landscape in Canada, the Canadian Leukemia Study Group (CLSG) conducted a survey of laboratory hematology leadership (n = 18) at 16 laboratories across 10 provinces, administered using Google Forms in September 2024. Nearly all surveyed sites were equipped to deliver a full suite of testing platforms through existing on-site infrastructure or laboratory partnerships. Reporting practices varied in terms of genomic integration into bone marrow results and the use of AML classification systems. Turn-around-time (TAT) targets were predominantly determined through internal institutional consensus (62%) or recommendations by provincial cancer agencies/international groups (44%). TAT reduction was a top priority for 56% of laboratories, suggesting timely biomarker results to be an active area for improvement. Various treatment-determining biomarkers were frequently assessed as rapid-tests (defined as a 5-day TAT), including

Indexed as

Leukemia, Myeloid, AcuteAdultBiomarkers, TumorCanadaHumansNucleophosminBiomarkers, TumorNucleophosminacute myeloid leukemiabiomarkerhematological pathologylaboratory hematologyquality improvementtargeted therapy

Identifiers

PMID42782852
PMCPMC13605815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.